When these rare endocrine tumors occur during pregnancy, they can mimic preeclampsia.
The small molecule ONC201 has shown promise as an effective, well-tolerated drug in the treatment of neuroendocrine tumors (NETs), report the authors of a Cleveland Clinic-led study.
Study authors characterize the incidence of head and neck tumors after treatment, and provide new insights on disease progression and surveillance recommendations.
There are conflicting guidelines from medical associations on how to follow head and neck paraganglioma patients. A new study, the largest of its kind, researchers track the longitudinal outcomes of second primary paraganglioma and offers recommendations on clinical surveillance of paragangliomas in the head and neck region.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A multidisciplinary effort involving Cleveland Clinic’s Head & Neck Institute, oncologists and medical geneticists attempts to identify and manage patients with genetic predispositions to paraganglioma.